Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IBRX

ImmunityBio Inc

Apr 17 • 04:00PM ET

5.24

Dollar change +0.32
Percentage change 6.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK LABU IWO SCHA DWAS PTH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	79.68%	Shs Outstand	670.87M	Perf Week	-12.08%
Market Cap	3.53B	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.00%	Shs Float	136.93M	Perf Month	0.19%
Income	-583.20M	PEG	-	EPS next Q	-0.16	Inst Own	8.49%	Short Float	40.00%	Perf Quarter	43.56%
Sales	0.62M	P/S	5695.96	EPS this Y	40.87%	Inst Trans	10.14%	Short Ratio	13.21	Perf Half Y	276.98%
Book/sh	-0.87	P/B	-	EPS next Y	33.82%	ROA	-134.56%	Short Interest	54.77M	Perf Year	137.10%
Cash/sh	0.40	P/C	13.25	EPS next 5Y	-1.70%	ROE	-	52W Range	1.25 - 6.93	Perf YTD	4.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.17%	ROI	-201.17%	52W High	-24.39%	Beta	1.19
Dividend TTM	-	Quick Ratio	5.05	Sales past 5Y	195.19%	Gross Margin	-3395.98%	52W Low	319.20%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	5.05	EPS Y/Y TTM	-8.15%	Oper. Margin	-58097.11%	RSI (14)	47.91	Volatility	13.18% 11.63%
Employees	628	Debt/Eq	-	Sales Y/Y TTM	159.17%	Profit Margin	-93761.41%	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-29.72%	Payout	-	Rel Volume	1.06	Prev Close	4.92
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	90.41%	Earnings	-	Avg Volume	4.15M	Price	5.24
SMA20	-6.68%	SMA50	3.26%	SMA200	56.33%	Trades		Volume	4,411,513	Change	6.50%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $4
Aug-03-22	Initiated	Jefferies	Buy	$8

Mar-19-24 09:53PM	IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-06-24 09:00AM	NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy (Business Wire) +5.39%
Mar-05-24 09:00AM	N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study (Business Wire)
Feb-21-24 09:00AM	ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial (Business Wire)
09:00AM	Loading…
Feb-05-24 09:00AM	ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG (Business Wire)
Jan-02-24 07:10AM	ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market (FierceBiotech.com)
06:00AM	ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million (Business Wire)
Nov-16-23 09:00AM	ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-07-23 09:00AM	First Data for ImmunityBios Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity (Business Wire)
Oct-26-23 09:00AM	FDA Accepts ImmunityBios BLA Resubmission as Complete and Sets New PDUFA Date (Business Wire) +29.75%
Oct-23-23 09:00AM	ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ (Business Wire) +10.00%
Oct-09-23 08:45AM	Lawsuit Notice: Investors who lost money with ImmunityBio, Inc. (NASDAQ: IBRX) shares should contact the Shareholders Foundation (GlobeNewswire)
Sep-11-23 06:00AM	ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities (Business Wire) +19.38%
Aug-03-23 09:00AM	ImmunityBio Names Enrique Diloné as Chief Technology Officer (Business Wire) +9.02%
08:32PM	Loading…
Jul-20-23 08:32PM	ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors (Business Wire) -6.77%
Jul-10-23 09:30AM	Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients (Business Wire)
May-22-23 09:00AM	ImmunityBio to Participate in the Jefferies Global Healthcare Conference (Business Wire) -6.06%
Apr-25-23 09:00AM	National Multicenter Trial Opens to Study ImmunityBios Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome (Business Wire)
Apr-24-23 11:28PM	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University (Business Wire) -8.96%
Feb-16-23 09:00AM	ImmunityBio to Present Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RFc superagonist N-803 plus BCG at ASCO GU (Business Wire) -7.71%
Feb-15-23 09:00AM	ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors (Business Wire) -6.42%
Jan-19-23 09:00AM	ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration (Business Wire)
Dec-12-22 08:30AM	ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor (Business Wire) +10.08%
Nov-17-22 09:00AM	ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-10-22 05:21PM	NEJM Evidence Publishes Results for ImmunityBios QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer (Business Wire) +20.23%
Oct-27-22 08:00AM	ImmunityBio to Participate in the Jefferies London Healthcare Conference (Business Wire)
Jul-28-22 04:18PM	ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ (Business Wire)
Jul-26-22 04:17PM	Fauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated' (Yahoo Finance)
Jun-30-22 10:00AM	ImmunityBio may have saved the day in Dunkirk, but it faces the same challenges as Athenex (American City Business Journals)
11:25AM	Loading…
Jun-14-22 11:25AM	Health authorities push for a vaccine patent waiver to 'genuinely' prepare for the next pandemic (Yahoo Finance)
Jun-06-22 09:00AM	ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting (Business Wire)
May-23-22 08:32AM	ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ (Business Wire)
May-16-22 07:29AM	What Percentage Of ImmunityBio, Inc. (NASDAQ:IBRX) Shares Do Insiders Own? (Simply Wall St.) +11.46%
Apr-28-22 09:00AM	ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-25-22 09:00AM	ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer (Business Wire)
Apr-01-22 04:15PM	ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ (Business Wire)
Mar-02-22 09:00AM	Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBios Scaled m-ceNK Clinical Program (Business Wire)
Feb-21-22 09:32AM	'The idea that there's not enough human capital in South Africa is outrageous': Dr. Patrick Soon-Shiong (Yahoo Finance)
Feb-18-22 12:13PM	Biden's renewed cancer moonshot is 'laudable effort': Dr. Patrick Soon-Shiong (Yahoo Finance)
Feb-15-22 09:00AM	ImmunityBio Completes Acquisition of Athenexs Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility (Business Wire) +22.26%
09:00AM	Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility (GlobeNewswire)
Feb-14-22 05:17PM	ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New Magnitude of Benefit in Patients with BCG Unresponsive Bladder Cancer (Business Wire)
Jan-31-22 07:16PM	ImmunityBio Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy (Business Wire) +12.57%
Jan-21-22 09:38PM	Liberty One Investment Management, Llc Buys Fastly Inc, Kratos Defense & Security Solutions ... (GuruFocus.com)
Jan-19-22 07:34AM	Billionaire Soon-Shiong Launches 1 Billion-Dose Vaccine Plant in Cape Town (Bloomberg)
Jan-18-22 06:00PM	ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival (Business Wire) -7.20%
Jan-13-22 09:00AM	Inside the Athenex-ImmunityBio deal and the California company's employment plans (American City Business Journals)
Jan-12-22 08:30AM	ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness (Business Wire)
08:30AM	Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility (GlobeNewswire)
Jan-04-22 09:00AM	ImmunityBio Awarded Seminal Patent on Natural Killer Cells (Business Wire) -6.91%
Jan-03-22 08:00AM	AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE (PR Newswire) +23.85%
Dec-20-21 09:00AM	ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing (Business Wire)
Dec-07-21 06:38AM	What Type Of Shareholders Own The Most Number of ImmunityBio, Inc. (NASDAQ:IBRX) Shares? (Simply Wall St.) +5.80%
Nov-18-21 09:00AM	ImmunityBio Expands Vaccine Program to Accelerate Use of "Mix-and-Match" Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines (Business Wire) -6.31%
Nov-08-21 05:14PM	Amyris takes bite out of sharks with Covid vaccine joint venture (American City Business Journals)
08:00AM	Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine (PR Newswire)
Nov-04-21 09:00AM	ImmunityBio to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-19-21 09:00AM	ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease (Business Wire)
Oct-13-21 09:00AM	ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients90% of Patients Have Exceeded Historical Survival Rates to Date (Business Wire)
Oct-04-21 08:30AM	National Cancer Institute Selects ImmunityBios N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy (Business Wire)
Sep-13-21 08:30AM	ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial (Business Wire)
Sep-07-21 08:30AM	ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives (Business Wire)
Sep-01-21 09:00AM	ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Associations Annual Meeting (Business Wire)
Aug-16-21 09:00AM	ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Companys Scientific Strategy and Global Expansion (Business Wire)
Jul-27-21 09:00AM	ImmunityBios Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent (Business Wire)
Jul-14-21 09:00AM	ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 (Business Wire)
Jun-28-21 09:00AM	ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients (Business Wire) +5.33%
Jun-23-21 04:05PM	Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee (GlobeNewswire)
Jun-15-21 07:00AM	FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer (Business Wire)
Jun-10-21 09:00AM	ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 HIV Cure Study in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients (Business Wire)
04:35AM	Do Insiders Own Lots Of Shares In ImmunityBio, Inc. (NASDAQ:IBRX)? (Simply Wall St.)
May-25-21 09:00AM	ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a Universal Boost in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa (Business Wire)
May-24-21 09:00AM	ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference (Business Wire)
May-20-21 09:00AM	ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021 (Business Wire) +6.70%
May-17-21 09:00AM	FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors (Business Wire) +9.65%
May-04-21 09:00AM	ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients (Business Wire) -8.35%
Apr-29-21 09:00AM	ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs (Business Wire) -7.24%
Apr-22-21 09:00AM	ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications (Business Wire)
Apr-08-21 09:00AM	ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2 (Business Wire)
Apr-01-21 09:00AM	ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors (Business Wire) -5.64%
Mar-29-21 09:00AM	ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer (Business Wire) -7.92%
Mar-26-21 03:04PM	'Unless we vaccinate the entire planet, we won't get rid of this pandemic:' Vaccine developer (Yahoo Finance) -13.31%
03:00PM	Yahoo Finance Presents: Dr. Patrick Soon-Shiong (Yahoo Finance Video)
Mar-22-21 09:00AM	ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors (Business Wire) +7.23%
Mar-15-21 09:00AM	ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations (Business Wire)
Mar-11-21 09:00AM	ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses (Business Wire) -12.07%
Mar-10-21 09:00AM	ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company (Business Wire) +19.11%

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adcock Richard	CEO & President	Feb 05 '24	Option Exercise	0.00	83,334	0	286,303	Feb 06 09:14 PM
Simon Barry J.	Director	Jan 31 '24	Option Exercise	0.00	57,200	0	3,145,855	Feb 02 07:38 PM
Sachs David C.	Chief Financial Officer	Jan 31 '24	Option Exercise	0.00	70,745	0	212,673	Feb 02 07:33 PM
LAUER REGAN J	Chief Accounting Officer	Jan 31 '24	Option Exercise	0.00	32,872	0	107,804	Feb 02 07:32 PM
Sachs David C.	Chief Financial Officer	Dec 31 '23	Option Exercise	0.00	30,397	0	152,439	Jan 03 09:41 PM
Adcock Richard	CEO & President	Dec 31 '23	Option Exercise	0.00	34,483	0	220,065	Jan 03 09:40 PM
LAUER REGAN J	Chief Accounting Officer	Dec 15 '23	Option Exercise	0.00	21,030	0	74,932	Dec 19 04:41 PM
Sachs David C.	Chief Financial Officer	Sep 01 '23	Option Exercise	0.00	70,744	0	122,042	Sep 06 07:41 PM
LAUER REGAN J	Chief Accounting Officer	Sep 01 '23	Option Exercise	0.00	32,872	0	53,902	Sep 06 07:40 PM
Simon Barry J.	Director	Sep 01 '23	Option Exercise	0.00	57,199	0	3,088,655	Sep 06 07:39 PM
LAUER REGAN J	Chief Accounting Officer	Jun 15 '23	Option Exercise	0.00	21,030	0	21,030	Jun 16 05:45 PM
BLASZYK MICHAEL D	Director	Jun 05 '23	Buy	2.75	71,915	198,023	71,915	Jun 05 09:52 PM
Brennan John Owen	Director	Jun 02 '23	Buy	2.83	25,000	70,700	25,000	Jun 05 07:55 PM
Clark Wesley	Director	Jun 01 '23	Buy	2.91	7,000	20,370	8,000	Jun 05 07:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBRX

ImmunityBio Inc

Upgrade your FINVIZ experience